» Articles » PMID: 24556353

Vasopressin-2 Receptor Signaling and Autosomal Dominant Polycystic Kidney Disease: from Bench to Bedside and Back Again

Overview
Specialty Nephrology
Date 2014 Feb 22
PMID 24556353
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Blockade of the vasopressin-2 receptor (V2R) in the kidney has recently emerged as a promising therapeutic strategy in autosomal dominant polycystic kidney disease. The pathophysiologic basis of V2R-dependent cyst proliferation and disease progression, however, is not fully understood. Recent evidence suggests that polycystic kidney disease is characterized by defects in urinary concentrating mechanisms and subsequent deregulation of vasopressin excretion by the neurohypophysis. On the cellular level, several recent studies revealed unexpected crosstalk of signaling pathways downstream of V2R activation in the kidney epithelium. This review summarizes some of the unexpected roles of V2R signaling and suggests that vasopressin signaling itself may contribute crucially to loss of polarity and enhanced proliferation in cystic kidney epithelium.

Citing Articles

Spot Versus 24-Hour Urine Osmolality Measurement in Autosomal Dominant Polycystic Kidney Disease: A Diagnostic Test Study.

Akbari A, Sriperumbuduri S, Mangalgi S, Joshi V, Sood M, Buh A Kidney Med. 2025; 7(3):100965.

PMID: 39980937 PMC: 11840182. DOI: 10.1016/j.xkme.2025.100965.


A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.

Stanajic-Petrovic G, Keck M, Barbe P, Urman A, Correia E, Isnard P J Am Soc Nephrol. 2024; 36(2):181-192.

PMID: 39431458 PMC: 11801765. DOI: 10.1681/ASN.0000000505.


PKD1 gene mutation and ultrasonographic characterization in cats with renal cysts.

Jaturanratsamee K, Jiwaganont P, Sukumolanan P, Petchdee S F1000Res. 2024; 12:760.

PMID: 39108347 PMC: 11301141. DOI: 10.12688/f1000research.134906.2.


Structural basis of tolvaptan binding to the vasopressin V receptor.

Liu H, Zhong H, Zhang Y, Xue H, Zhang Z, Fu K Acta Pharmacol Sin. 2024; 45(11):2441-2449.

PMID: 38902502 PMC: 11489814. DOI: 10.1038/s41401-024-01325-5.


Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4.

Gobburu J, Ivaturi V, Wang X, Shoaf S, Jadhav P, Perrone R Kidney360. 2023; 4(12):1702-1707.

PMID: 37986188 PMC: 10758521. DOI: 10.34067/KID.0000000000000302.


References
1.
Zha J, Harada H, Yang E, Jockel J, Korsmeyer S . Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996; 87(4):619-28. DOI: 10.1016/s0092-8674(00)81382-3. View

2.
Pinto C, Reif G, Nivens E, White C, Wallace D . Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells. Am J Physiol Renal Physiol. 2012; 303(10):F1412-24. PMC: 3517630. DOI: 10.1152/ajprenal.00692.2011. View

3.
Hartwig J, Ausiello D, Brown D . Vasopressin-induced changes in the three-dimensional structure of toad bladder apical surface. Am J Physiol. 1987; 253(5 Pt 1):C707-20. DOI: 10.1152/ajpcell.1987.253.5.C707. View

4.
Gabow P, Kaehny W, Johnson A, Duley I, Manco-Johnson M, Lezotte D . The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int. 1989; 35(2):675-80. DOI: 10.1038/ki.1989.38. View

5.
Park F, Mattson D, Skelton M, Cowley Jr A . Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation. Am J Physiol. 1997; 273(1 Pt 2):R243-51. DOI: 10.1152/ajpregu.1997.273.1.R243. View